INTRODUCTION
South Africa has one of the most rapidly growing human immune defi ciency virus (HIV) epidemics in the world with an estimated 5.7 million HIV positive people.
(1) Of the 6 800 new HIV infections that occurred per day in the world in 2007, more than two out of three adults (68%) and nearly 90% of children infected with HIV live in Sub-Saharan Africa. (1) Although 18% of these infections occurred in young adults (15-49 years) little attention has been paid to the comor bidity associated with HIV seropositivity. In fact, except for tuberculosis and opportunistic infections, there are no specifi c guidelines that are available for the management of different comorbid diseases in these patients that demand attention in their own right.
Most decision-making regarding management in HIV patients is infl uenced by immune status, often taking the CD4 count into consideration. However, it is not infrequent that arbitrary decision-making approaches are adopted, and intervention/ surgery turned down on the basis of HIV seropositivity alone. morbidity and mortality. The spectrum ranges from pericardial disease with effusion, to myocardial disease, as well as involvement of the valve endocardium. With the advent of highly active antiretroviral therapy (HAART), coronary artery disease and dyslipidaemia, drug-related cardiotoxicity and cardiac autonomic dysfunction have begun to emerge and are becoming increasingly prevalent.
MYOCARDIAL INVOLVEMENT IN HIV
Little change in cardiac function has been documented in ambulatory HIV positive patients. (8, 9) Diastolic abnormalities have been reported in patients without clinical evidence of cardiac disease. (10) Advanced systolic dysfunction is more common in the patients classifi ed as having Aids, (8) but there has been a decline in cardiomyopathy with the advent of HAART in the developed countries. (11) In contrast heart involvement in developing countries is dominated by pericardial tuberculosis, often accompanied by impairment of left ventricular function due to associated myocarditis. (12, 13, 14) In prospective cross sectional studies in Africa which have included patients with Aids, the prevalence of dilated cardiomyopathy has been reported to vary from 15% to 35% (15, 16, 17) compared to the 15% overall reported in a western series by Currie. (18) A study from Cameroon evaluated cardiac involvement in 75 African patients according to the clinical stage of the disease and the immunological status of the patients. (15) This study found that dilated cardiomyopathy occurred in 7/30 (23.33%)
of Aids patients, 1/24 (4.17%) HIV positive non-Aids patient, but in none of the HIV negative subjects. In this study dilated cardiomyopathy occurred in six (31.58%) of the patients with a CD4
cell count Ϲ 100 cells/microlitre and in two (6.06%) with CD4
counts > 100 cells/microlitre (chi2 = 4.02, p = 0.03). This association of cardiomyopathy with more advanced immunosuppression and lower CD4 counts is consistent with international experience. (18) Global left ventricular dysfunction is typically found in the late stages of HIV infection. The clinical picture of dilated cardiomyopathy is strongly associated with CD4 counts < 100 cells/ microlitre.
ACUTE INFECTION AND LV DYSFUNCTION
The cause of heart muscle disease in patients with HIV infection is not clear. Autopsy studies document a high prevalence of myocarditis (46%), but in over 80% of cases no specifi c aetiology has been found. Many cases seem to be related to a lymphocytic myocarditis directly related to the HIV infection, while opportunistic infection accounts for the remaining 20% (examples being cytomegalovirus/toxoplasma gondii infection). (18) Other potential pathogenic factors include nutritional defi ciencies, the cardiotoxic effects of antiretroviral drugs and other opportunistic infections.
Regardless of its aetiology the presence of impaired left ventricular function in these subjects is an independent adverse prognostic factor; it is associated with very low CD4 counts and with reduced survival compared to those with normal hearts, 18
which poses serious challenges in the medical and surgical treatment of valve-related disease. 
VALVE INVOLVEMENT IN HIV
To date most reports on valvular heart disease (VHD) in HIV infected patients have focused on infective endocarditis (IE) in drug addicts. (19, 20, 21, 22, 23) If, as Levy suggested, the risk of developing IE in HIV positive patients is related to the degree of immune paresis (3) then one would expect low CD4 counts to increase the risk of bacteremia, and subsequent seeding on the valve tissue would predispose to infective endocarditis, particularly in subjects with a predisposing valve/cardiac lesion.
Bacteremia is indeed common in the HIV positive patients, due to the numerous immunologic defects present in this disease. (24) IE is reported to be common in advanced HIV patients, and mortality increases with a decreasing CD4 count. (19, 25) The rise in staphylococcal infections, and the immune paresis associated with Aids pose diagnostic challenges, and they also have important implications for management in these patients. (25) Furthermore infection may be caused by unusual organisms, such as bartonella, salmonella and listeria. (26, 27) Although infective endocarditis is the most common cardiac complication of HIV/Aids in the Western world, (20) the clinical outcome in these patients appears to depend more on the valve affected and the virulence of the organism rather than the HIV serostatus. (20) In a large series of 263 cases of defi nite IE (Dukes criteria), including a 100 cases in HIV positive patients, over a 13-year period in intravenous drug users between 1986 and 1999 in the pre-HAART era De Rosa found no major differences in outcome between HIV negative and HIV positive patients. (21) In another large series of 493 cases of native valve endocarditis (220 cases in intravenous drug users) diagnosed from 1985 to 1999 MartinDavila analysed 13 variables, including HIV serostatus and CD4 cell count < 200 cells/microlitre, and showed that the main prognostic factors of in-hospital mortality in right-sided IE were large vegetations > 2 cm and fungal etiology. (28) As with cardiomyopathy it is reported that IE rates have decreased in the current HAART era from 20.5 to 6.6 per 1 000-person-years (29) accompanied by an appearance of noninfective valvular disease (marantic and rheumatic causes NIVD) and coronary artery disease (CAD) in HIV patients. (5, 30) 
HIV ASSOCIATED INFECTIVE ENDOCARDITIS

IN AFRICA
There are few reports of infective endocarditis in HIV/Aids from developing countries. (31, 32) Despite the high prevalence of rheumatic heart disease it is distinctly uncommon in our environment, probably due to the low prevalence of mainline drug addiction. A 3-year survey of IE at our centre found that the clinical profi le in the HIV positive patient was similar to the HIV negative patient, and was characterised by fever, clubbing, murmurs and severe valve regurgitation with similar responses to therapy. (32) The CD4 counts in 4/17 HIV infected patients who demised were 139, 135, 149 and 249 cells/microlitre3. This is in contrast to the fi ndings of the Emory group who suggested that there was no correlation between the mortality and the degree of immunosuppression. (24, 33) The most common underlying predisposing abnormality in our series is rheumatic heart disease. Although S.aureus and S.viridans are the common infecting organisms, (20) a high rate of culture negativity has been reported (31, 32) probably related to prior antibiotic therapy, and in the absence of microbiological indices the sensitivity of the modifi ed Duke criteria is diminished. (34) The lack of specifi city in echocardiographic criteria becomes apparent when diagnosing IE in the HIV population, as these patients often have elevated ESR and CRP levels due to anaemia or non-valvular infection.
Furthermore it is also being increasingly recognised that nonbacterial thrombotic endocarditis (NBTE) may be the cause when blood culture is negative. (35) NBTE is characterised by the of fi brin and platelet aggregates and is being increasingly recognised as a potentially life-threatening source of thromboembolism. NBTE occurs in 3 to 5% of Aids patients, mostly in patients with extreme wasting. It is often diffi cult to diagnose and one has to rely on strong clinical suspicion. Even with an established diagnosis, treatment of NBTE is diffi cult. In the non-HIV patients anticoagulation has been instituted although there are no prospective randomised studies to support this strategy.
There are also no guidelines for surgical intervention in patients with NBTE. Systemic embolisation from marantic endocarditis in the Aids patient is a rare cause of death in the HAART era.
In haemodynamically stable patients surgical intervention is generally not recommended unless the patient develops severe valve damage with resultant heart failure. Signifi cant morbidity was present in these patients, such as anaemia, concomitant TB and dialysis-requiring renal failure. (26) Nosocomial infection leading to prosthetic valve and catheterrelated endocarditis poses serious challenges in management because of the emergence of antibiotic resistance among causative organisms. (29) 
EFFECTS OF IMMUNE SUPPRESSION ON CLINICAL MANIFESTATIONS AND OUTCOME
It is not
IMPACT OF HIV SEROSTATUS ON UNDERLYING VALVULAR HEART DISEASE:
Information from a cardiac disease in pregnancy cohort
Women of reproductive age are the fastest growing population with HIV, and in developing countries rheumatic heart disease (RHD) is a major cause of maternal morbidity (37) and mortality. (38, 39) Recent reviews have not focused on the impact of HIV serostatus in these patients. (40, 41) Two studies have shown that HIV serostatus does not modify the treatment effects in patients with cardiac disease during pregnancy. (42, 43) In a one year review of 95 patients with cardiac disease in pregnancy during 2003. Cardiac complications were mainly related to rhythm disturbances and heart failure while bleeding from over-anticoagulation accounted for the majority of the non-cardiac complications (Table 3) . Maternal morbidity and adverse fetal outcomes were associated with late presentation and problems with anticoagulation, not with HIV serostatus.
Outcome measures were similar in HIV-infected and non-infected groups ( Table 5 ). The mean CD4 count was 463 cells/microlitre (range 79-1419). The ejection fraction was normal in all patients except for three with cardiomyopathy (Table 2) . Of note Nqayana found that HIV infected women did not have a higher wound infection rate, puerperal sepsis rate, nor was there a higher neo- 
IMPACT OF HIV SEROSTATUS AND COMORBIDITY IN PATIENTS UNDERGOING CARDIAC VALVE SURGERY
To date, most valve surgery has been in patients with infective endocarditis related to intravenous drug use (Table 3) . Recently 
ISSUES RELATED TO CARDIAC SURGERY (TABLE 4)
While it is recognised hospital mortality and pneumonia in HIV patients are higher than in uninfected cases in some series, (47, 48) a retrospective analysis of patients undergoing general surgical procedures has shown that other operative outcomes were comparable for HIV infected and non-HIV infected patients. (48) Hospital mortality and complications in Blyth's series were acceptably low (6% and 34.7% respectively) in a selected group of patients (CD4 count >400 cells/microlitre). Furthermore, except for undiagnosed preoperative infection (Tuberculosis1 and infective endocarditis1) he did not fi nd a higher wound infection rate in his patients; even the commonest early complication, pericardial 
Bleeding complications and anticoagulant therapy in HIV patients
Treatment response and the effects of HIV on healing process
Emerging challenges
Emergence of prosthetic valve and pacemaker-related endocarditis increase in antibiotic resistance among aetiologic organisms e.g. MRSA Increase in comorbid disease eg atherosclerosis, diabetes, dialysis-dependent renal failure, and drug abuse. (8) Acute phase reactants (CRP and ESR often related to opportunistic infection, anaemia)
High prevalence of tuberculosis co-infection
Simultaneous anti-tuberculous therapy and HAART HAART in the peri-operative period
Issues in surgical management
Prioritising against surgery in the HIV patient:
• Perception that surgery may accelerate the disease process during CPB is not associated with disease progression even when counts are low. (30, 52, 53) Also the recurrence of endocarditis in patients operated upon during the phase of active infection (54, 55) has been found to be related to continuing intravenous drug abuse, and not due to the HIV status. Since the report by Mellors et al. There is no scientifi c basis to:
• deny any intervention because of HIV infection;
• discriminate in favour of non-HIV status; and
• refuse to operate because of the risk of exposure.
Operative/interventional outcomes are similar for HIV infected and non-HIV 
Assessment of haemodynamic status and ventricular function
Of importance is a determination of the possible cause and severity of ventricular dysfunction when it is present. HIV related myocarditis consists of a cell-mediated injury of the myocytes and phenotypically appears identical to a subgroup of non-HIV positive patients. (57) There is therefore little to be gained by performing myocardial biopsies in these patients prior to surgery.
Furthermore, no prospective studies have evaluated the treatment regimens in HIV associated cardiomyopathy.
A decline in the incidence of HIV associated cardiomyopathy that has been documented in the post HAART era, suggests that the administration of HAART prevents opportunistic infection and could, in this way, reduce the incidence of pericardial effusion and myocardial involvement in these patients.
The development of severe pulmonary hypertension in the patient with valve disease may present a diagnostic dilemma. It may be secondary to left-sided valve disease or it may be due to the HIV itself. HIV associated pulmonary hypertension is a well- It should be considered when the pulmonary hypertension is clearly out of proportion to the severity of valve involvement.
Increased atherosclerotic risk
The administration of HAART has been associated with an increase in the incidence of coronary heart disease in patients receiving protease inhibitors. (58) Recent reports also indicate that the metabolic changes associated with these drugs is accompanied by elevation in blood pressure in up to 74% of patients with metabolic syndrome. Careful screening is therefore essential in patients who are receiving HAART, especially in those with risk factors for coronary disease, as the atherogenic effect of treatment may accelerate this risk.
Effects of antiretroviral therapy
The improved survival of patients with HIV infection who have access to HAART has resulted in HIV becoming a chronic viral disease with a growing disease burden. The 5-year survival after surgery has improved from 48% (59) to 64.9% at one year (30) and in another study has been documented to be over 80% at 3 years (46, 52) in the post-HAART era. The marked improvement in mortality with the use of ARVs reported by Palella (59) supports the contention that all patients should be offered surgery where it is indicated.
Ethical issues
Although surgeons are prepared to operate on HIV carriers most are still are reluctant to operate on patients with Aids (54, 60) despite the low risk of accidental skin injury. Legal and ethical issues arise when patients are denied appropriate care without adequate grounds for such decisions being clear and documented.
In the US (61) p=0.007). (48) Viral suppression to fewer than 30000 copies/ml reduced surgical complications. However, in this study Horberg pointed out that a CD4 count <200 was not associated with poorer outcomes.
Although there was a higher rate of complications, Blyth found no increase in infections in his study. He therefore felt that patients with low counts could be placed on a waiting list while receiving HAART. It has been well described that six months after starting HAART, the achieved CD4 cell count and viral load, but not values at baseline, are strongly associated with subsequent disease progression. These fi ndings should inform our guidelines on selection for surgery and when to modify HAART in these patients. (65) We now perform routine voluntary HIV testing for all patients with VHD in whom intervention is imminent. As there are few operative guidelines (63) If the patient is in good general health, with a low viral load and without serious comorbidity, surgery is offered regardless of the CD4 count.
Where the clinical staging and CD4 count is Aids defi ning (<200 cells/microlitre), palliative treatment is administered unless surgery is deemed life-saving (e.g. stuck valve, atrial myxoma) and the patient is otherwise in good health. Clinical and immunological staging should be applied using appropriate measures (CD4 count/ CD4/8 ratio/ CD 4 % and viral load)
CONCLUSION
HAART should be initiated without delay where indicated
Evaluation of comorbidity
Estimation of acute phase reactants (ESR, CRP viral vs bacterial) to assess the activity of comorbid disease, including infection and carditis
Where endocarditis is suspected, blood cultures should be taken frequently, and where possible, prior to antibiotic therapy Aggressive treatment of coexistent infection (tuberculosis), and other comorbidities
Diagnostic evaluation
Careful evaluation of disease severity including transthoracic echo (TTE) to:
• evaluate the severity of valve dysfunction;
• detect evidence of infective endocarditis (vegetations, paravalvular extension, prosthetic valve dehiscence); and
• document ventricular dimensions and ventricular function.
Transesophageal echo should be performed where TTE images are suboptimal, with mechanical prosthetic valves, or if paravalvular infection is suspected:
• adequate sterilisation of the transducer is a critical requirement since the risk of trauma during passage of the scope is likely to be associated with bleeding in the presence of oesophageal candidiasis;
• using a protective sheath and gumguard; and
• observe the usual precautions against needlestick injury -fully equipped crashcart on standby.
